US20070187405A1 - Container for compositions containing cefdinir - Google Patents
Container for compositions containing cefdinir Download PDFInfo
- Publication number
- US20070187405A1 US20070187405A1 US11/621,440 US62144007A US2007187405A1 US 20070187405 A1 US20070187405 A1 US 20070187405A1 US 62144007 A US62144007 A US 62144007A US 2007187405 A1 US2007187405 A1 US 2007187405A1
- Authority
- US
- United States
- Prior art keywords
- cefdinir
- sodium benzoate
- container
- remains
- theoretical amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 title claims abstract description 127
- 229960003719 cefdinir Drugs 0.000 title claims abstract description 127
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 229920003023 plastic Polymers 0.000 claims abstract description 33
- 239000004033 plastic Substances 0.000 claims abstract description 33
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 77
- 235000010234 sodium benzoate Nutrition 0.000 claims description 77
- 239000004299 sodium benzoate Substances 0.000 claims description 77
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 229920000089 Cyclic olefin copolymer Polymers 0.000 claims description 26
- 239000004713 Cyclic olefin copolymer Substances 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 22
- -1 polyethylene Polymers 0.000 claims description 21
- 239000000725 suspension Substances 0.000 claims description 21
- 239000004698 Polyethylene Substances 0.000 claims description 19
- 229920000573 polyethylene Polymers 0.000 claims description 19
- 125000005487 naphthalate group Chemical group 0.000 claims description 18
- 238000004321 preservation Methods 0.000 abstract description 3
- 239000011521 glass Substances 0.000 description 6
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 4
- 229920001903 high density polyethylene Polymers 0.000 description 4
- 239000004700 high-density polyethylene Substances 0.000 description 4
- 229920009441 perflouroethylene propylene Polymers 0.000 description 4
- 239000004734 Polyphenylene sulfide Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 229920000069 polyphenylene sulfide Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 238000003556 assay Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 239000011112 polyethylene naphthalate Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- CHJAYYWUZLWNSQ-UHFFFAOYSA-N 1-chloro-1,2,2-trifluoroethene;ethene Chemical group C=C.FC(F)=C(F)Cl CHJAYYWUZLWNSQ-UHFFFAOYSA-N 0.000 description 1
- 229920001780 ECTFE Polymers 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Plastic containers for storage and preservation of compositions comprising cefdinir are disclosed.
Description
- This application claims priority to U.S. Provisional Patent Application No. 60/761,199, filed Jan. 23, 2006.
- This invention pertains to plastic containers for storage and preservation of compositions comprising cefdinir.
- Cefdinir, an antibiotic available as capsules and powder for reconstituted suspension, is transported and stored in glass containers. To improve safety and handling of cefdinir, there is an existing need in the therapeutic arts for a less breakable container in which the cefdinir may be transported and stored.
-
FIG. 1 shows the effect of plastic type on cefdinir amount over time. -
FIG. 2 shows the effect of plastic type on sodium benzoate amount over time. -
FIG. 3 shows a preferred shape for a plastic container. - One embodiment of this invention pertains to a plastic container having a closure device for storing and preserving compositions comprising sodium benzoate and cefdinir, wherein the percentage of the sodium benzoate or the cefdinir remains substantially unchanged over time.
- Another embodiment pertains to a plastic container having a closure device for storing and preserving compositions comprising sodium benzoate and cefdinir, wherein the percentage of the sodium benzoate and the cefdinir remains substantially unchanged over time.
- This invention pertains to plastic containers for storage and preservation of compositions comprising cefdinir.
- One embodiment of this invention pertains to a plastic container having a closure device for storing and preserving compositions comprising sodium benzoate and cefdinir, wherein the percentage of the sodium benzoate or the cefdinir remains substantially unchanged over time.
- Another embodiment pertains to a plastic container having a closure device for storing and preserving compositions comprising sodium benzoate and cefdinir, wherein the cefdinir remains at least at about 90% of its original theoretical amount or sodium benzoate remains at least at about 80% of its original theoretical amount.
- Still another embodiment pertains to a plastic container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein, after 24 months, the cefdinir remains at least at about 90% of its original theoretical amount or the sodium benzoate remains at least at about 80% of its original theoretical amount.
- Still another embodiment pertains to a polyethylene naphthylate container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir.
- Still another embodiment pertains to a polyethylene naphthylate container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein the cefdinir remains at least at about 90% of its original theoretical amount or the sodium benzoate remains at least at about 80% of its original theoretical amount.
- Still another embodiment pertains to a polyethylene naphthylate container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein, after 24 months, the cefdinir remains at least at about 90% of its original theoretical amount or the sodium benzoate remains at least at about 80% of its original theoretical amount.
- Still another embodiment pertains to a cyclic olefin copolymer container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir.
- Still another embodiment pertains to a cyclic olefin copolymer container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein the cefdinir remains at least at about 90% of its original theoretical amount or the sodium benzoate remains at least at about 80% of its original theoretical amount.
- Still another embodiment pertains to a cyclic olefin copolymer container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein, after 24 months, the cefdinir remains at least at about 90% of its original theoretical amount or the sodium benzoate remains at least at about 80% of its original theoretical amount.
- Still another embodiment pertains to a plastic container having a closure device for storing and preserving compositions comprising sodium benzoate and cefdinir, wherein the percentage of the sodium benzoate and the cefdinir remains substantially unchanged over time.
- Still another embodiment pertains to a plastic container having a closure device for storing and preserving compositions comprising sodium benzoate and cefdinir, wherein the cefdinir remains at least at about 90% of its original theoretical amount and the sodium benzoate remains at least at about 80% of its original theoretical amount.
- Still another embodiment pertains to a plastic container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein, after 24 months, the cefdinir remains at least at about 90% of its original theoretical amount and the sodium benzoate remains at least at about 80% of its original theoretical amount.
- Still another embodiment pertains to a polyethylene naphthylate container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir.
- Still another embodiment pertains to a polyethylene naphthylate container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein the cefdinir remains at least at about 90% of its original theoretical amount and the sodium benzoate remains at least at about 80% of its original theoretical amount.
- Still another embodiment pertains to a polyethylene naphthylate container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein, after 24 months, the cefdinir remains at least at about 90% of its original theoretical amount and the sodium benzoate remains at least at about 80% of its original theoretical amount.
- Still another embodiment pertains to a cyclic olefin copolymer container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir.
- Still another embodiment pertains to a cyclic olefin copolymer container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein the cefdinir remains at least at about 90% of its original theoretical amount and the sodium benzoate remains at least at about 80% of its original theoretical amount.
- Still another embodiment pertains to a cyclic olefin copolymer container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein, after 24 months, the cefdinir remains at least at about 90% of its original theoretical amount and the sodium benzoate remains at least at about 80% of its original theoretical amount.
- The term “substantially unchanged,” as used herein in reference to cefdinir, means remains at least at about 90% of its original theoretical amount, preferably at least at about 95% of its original theoretical amount, more preferably at least at about 98% of its original theoretical amount, most preferably at least at about 99% of its original theoretical amount.
- The term “substantially unchanged,” as used herein in reference to sodium benzoate, means remains at least at about 80% of its original theoretical amount, preferably at least at about 90% of its original theoretical amount, more preferably at least at about 95% of its original theoretical amount, most preferably at least at about 99% of its original theoretical amount.
- The cefdinir of this invention may be in a physical form such as powders, pellets or granules. In a preferred embodiment for the practice of this invention the cefdinir is in powder form for reconstitution in suspension.
- The amount of cefdinir in a sample removed from a container, based on a formula composition for its label indication (its original theoretical amount), is typically between about 90% and 100% of its original theoretical amount.
- For example, for a teaspoon of a composition comprising cefdinir powder for reconstituted suspension with a label indication that claims that 250 mg of cefdinir will be in that teaspoon, the amount of cefdinir in that teaspoon may be about 90% to about 100% of the 250 mg.
-
FIG. 3 shows aplastic container 1, provided with aconventional closure device 2, that is useful for storing and preserving compositions comprising sodium benzoate andcefdinir 3. It is meant to be understood that thecontainer 1 shown inFIG. 3 is a preferred embodiment for the practice of this invention and that a container of any shape for storing and preserving pharmaceutical compositions comprising cefdinir can be made from a plastic in which the percentage of the cefdinir in the compositions remains substantially constant over time. - In a study with HDPE and triple layer bottles (PET/COC/PET), it was noted that a substantial reduction in the amount of sodium benzoate and original theoretical amounts of cefdinir occurred over time. It was also noted that the reduction of the original theoretical amounts of cefdinir in the composition accelerated when the amount of sodium benzoate in the same composition dropped to below about 90% of its original amount.
- A rapid screening study was designed to evaluate plastics that might cause reduction in the amount of sodium benzoate. The plastics tested are shown in TABLE 1.
TABLE 1 Plastic Abbreviation Cyclic Olefin Copolymer 8007 D-61 COC Ethylene Chlorotrifluoroethylene E-CTFE Fluorinated ethylenepropylene FEP High-density Polyethylene 5502 BN HDPE Polyethylene naphthylate 75-3177 PEN Polyethylene terphthalate 79921 PET Polyphenylenesulfide Fotran 9320C0 PPS Polypropylene FT120WB PP Polystyrene 3510 PS Polyvinyl chloride PVC - Based on the results of this study, shown in TABLE 2, PEN and COC were chosen for further evaluation.
TABLE 2 Plastic Beads % Loss After 1 Week % Loss After 2 Weeks PEN 6.5 13.8 PPS 4.0 17.7 polystyrene 11.9 18.0 COC 11.5 19.8 PET 10.2 20.3 polypropylene 14.4 20.3 HDPE 22.9 22.3 PVC 15.9 24.9 control (1) −1.3 0.4 control (2) 7.8 17.4
% loss are w/w percentages
(1) without beads and without salt solution and
(2) without beads and with salt solution
- Bottles made from PEN and COC were charged with active granulation and placed on an accelerated stability study at 25° C./60% relative humidity for 24 months along with glass bottles that served as controls. The contents of the bottles were tested at pre-determined time points for cefdinir and sodium benzoate concentration.
- As shown in
FIG. 1 , results from the stability study indicate that the assay values of cefdinir were greater than 90% for the glass, PEN and COC bottles. The sodium benzoate values for the glass, PEN and COC bottles also remained substantially constant over the duration of the study. - Additionally, bottles made from E-CTFE and FEP were charged with active granulation and placed on an accelerated stability study at 40° C./75% relative humidity for 6 months along with glass bottles that served as controls. The contents of the bottles were tested at pre-determined time points for cefdinir and sodium benzoate concentration. Results from this stability study indicated that the assay values for the glass, E-CTFE and FEP bottles remained substantially constant over the duration of the study.
- The foregoing is meant to illustrate the invention but not to limit it. Variations and changes obvious to one skilled in the art are intended to be within the scope of the invention as defined in the claims.
Claims (36)
1. A plastic container having a closure device for storing and preserving compositions comprising sodium benzoate and cefdinir, wherein the percentage of the sodium benzoate or the cefdinir remains substantially unchanged over time.
2. The plastic container of claim 1 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
3. A plastic container having a closure device for storing and preserving compositions comprising sodium benzoate and cefdinir, wherein the cefdinir remains at least at about 90% of its original theoretical amount or the sodium benzoate remains at least at about 80% of its original theoretical amount.
4. The plastic container of claim 3 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
5. A plastic container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein, after 24 months, the cefdinir remains at least at about 90% of its original theoretical amount or the sodium benzoate remains at least at about 80% of its original theoretical amount.
6. The plastic container of claim 5 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
7. A polyethylene naphthylate container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir.
8. The plastic container of claim 7 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
9. A polyethylene naphthylate container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein the cefdinir remains at least at about 90% of its original theoretical amount or the sodium benzoate remains at least at about 80% of its original theoretical amount.
10. The polyethylene naphthylate container of claim 9 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
11. A polyethylene naphthylate container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein, after 24 months, the cefdinir remains at least at about 90% of its original theoretical amount or the sodium benzoate remains at least at about 80% of its original theoretical amount.
12. The polyethylene naphthylate container of claim 11 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
13. A cyclic olefin copolymer container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir.
14. The cyclic olefin copolymer container of claim 13 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
15. A cyclic olefin copolymer container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein the cefdinir remains at least at about 90% of its original theoretical amount or the sodium benzoate remains at least at about 80% of its original theoretical amount.
16. The cyclic olefin copolymer container of claim 15 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
17. A cyclic olefin copolymer container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein, after 24 months, the cefdinir remains at least at about 90% of its original theoretical amount or the sodium benzoate remains at least at about 80% of its original theoretical amount.
18. The cyclic olefin copolymer container of claim 17 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
19. A plastic container having a closure device for storing and preserving compositions comprising sodium benzoate and cefdinir, wherein the percentage of the sodium benzoate and the cefdinir remains substantially unchanged over time.
20. The plastic container of claim 19 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
21. A plastic container having a closure device for storing and preserving compositions comprising sodium benzoate and cefdinir, wherein the cefdinir remains at least at about 90% of its original theoretical amount and the sodium benzoate remains at least at about 80% of its original theoretical amount.
22. The plastic container of claim 21 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
23. A plastic container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein, after 24 months, the cefdinir remains at least at about 90% of its original theoretical amount and the sodium benzoate remains at least at about 80% of its original theoretical amount.
24. The plastic container of claim 23 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
25. A polyethylene naphthylate container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir.
26. The polyethylene naphthylate container of claim 25 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
27. A polyethylene naphthylate container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein the cefdinir remains at least at about 90% of its original theoretical amount and the sodium benzoate remains at least at about 80% of its original theoretical amount.
28. The polyethylene naphthylate container of claim 27 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
29. A polyethylene naphthylate container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein, after 24 months, the cefdinir remains at least at about 90% of its original theoretical amount and the sodium benzoate remains at least at about 80% of its original theoretical amount.
30. The polyethylene naphthylate container of claim 29 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
31. A cyclic olefin copolymer container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir.
32. The cyclic olefin copolymer container of claim 31 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
33. A cyclic olefin copolymer container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein the cefdinir remains at least at about 90% of its original theoretical amount and the sodium benzoate remains at least at about 80% of its original theoretical amount.
34. The cyclic olefin copolymer container of claim 33 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
35. A cyclic olefin copolymer container having a closure device for storing and preserving pharmaceutical compositions comprising sodium benzoate and cefdinir, wherein, after 24 months, the cefdinir remains at least at about 90% of its original theoretical amount and the sodium benzoate remains at least at about 80% of its original theoretical amount.
36. The cyclic olefin copolymer container of claim 35 , wherein the cefdinir therein is cefdinir powder for reconstituted suspension.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/621,440 US20070187405A1 (en) | 2006-01-23 | 2007-01-09 | Container for compositions containing cefdinir |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76119906P | 2006-01-23 | 2006-01-23 | |
| US11/621,440 US20070187405A1 (en) | 2006-01-23 | 2007-01-09 | Container for compositions containing cefdinir |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20070187405A1 true US20070187405A1 (en) | 2007-08-16 |
Family
ID=38093343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/621,440 Abandoned US20070187405A1 (en) | 2006-01-23 | 2007-01-09 | Container for compositions containing cefdinir |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US20070187405A1 (en) |
| WO (1) | WO2007087214A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10161077A1 (en) | 2001-12-12 | 2003-06-18 | Boehringer Ingelheim Vetmed | Highly concentrated stable meloxicam solutions for needleless injection |
| US8992980B2 (en) | 2002-10-25 | 2015-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Water-soluble meloxicam granules |
| EP1568369A1 (en) | 2004-02-23 | 2005-08-31 | Boehringer Ingelheim Vetmedica Gmbh | Use of meloxicam for the treatment of respiratory diseases in pigs |
| WO2011046853A1 (en) | 2009-10-12 | 2011-04-21 | Boehringer Ingelheim Vetmedica Gmbh | Containers for compositions comprising meloxicam |
| SG183846A1 (en) | 2010-03-03 | 2012-10-30 | Boehringer Ingelheim Vetmed | Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats |
| US9795568B2 (en) | 2010-05-05 | 2017-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Low concentration meloxicam tablets |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0169505B1 (en) * | 1992-09-11 | 1999-01-15 | 오오쓰끼 아끼히꼬 | Drug packing polyolefinic material, process for producing the same and container for drug packing |
| JP2007532416A (en) * | 2004-04-08 | 2007-11-15 | アイディーディー−イール マニュファクチャリング カンパニー リミテッド | Container for preparing liquid formulations |
-
2007
- 2007-01-09 US US11/621,440 patent/US20070187405A1/en not_active Abandoned
- 2007-01-19 WO PCT/US2007/001275 patent/WO2007087214A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007087214A1 (en) | 2007-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070187405A1 (en) | Container for compositions containing cefdinir | |
| US11801989B2 (en) | Container for medical and/or pharmaceutical products | |
| JP3359305B2 (en) | Pharmaceutical composition containing potassium clavulanate and crystalline amoxicillin sodium | |
| US9522222B2 (en) | Application arrangement with a medicinal substance fluid | |
| US20210128562A1 (en) | Intravenous infusion dosage form | |
| US20170231869A1 (en) | Bottle support shoe with suction base | |
| US20030042166A1 (en) | Pharmaceutical kit for oxygen-sensitive drugs | |
| EP2488145B1 (en) | Containers for compositions comprising meloxicam | |
| JPH10512521A (en) | package | |
| SA99200573A (en) | Improved stability for injection solutions | |
| Lyashenko et al. | Features of packaging from polymers in pharmaceutics | |
| EP3456532A1 (en) | Medical packaging film | |
| US20140309299A1 (en) | Stabilized Pharmaceutical Preparations in Containers Having Limited Perviousness to Water Vapor | |
| CA1231059A (en) | Pharmaceutical compositions for storage in plastic containers and process for preparing such compositions | |
| CN110317388A (en) | A kind of packaging material and its preparation method and application directly contacted with drug | |
| CN1070763C (en) | Polyolefin packaging material for drug packaging, method of production thereof and containers for drug packaging | |
| JP2014073496A (en) | Resin molded article having moisture absorption capability and drying container using the same | |
| KR100219975B1 (en) | Method of suppressing absorption of substances derived from container material on drugs and container | |
| KR102415182B1 (en) | Preservation container and preservation method of crystalline L-carnosine zinc complex | |
| EP3902755B1 (en) | A tablet dispensing device | |
| WO2020036136A1 (en) | Packaged article having culture medium container therein | |
| US20220073255A1 (en) | Compound material, container and sterile product | |
| KR20240004368A (en) | Dexmedetomidine solution in a low-density polyethylene container. | |
| WO2020257134A1 (en) | Protection of oxygen sensitive compounds | |
| CN115240891A (en) | Transport container for radiopharmaceuticals and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: ABBOTT LABORATORIES, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PUJARA, CHETAN P.;KIM, DANIEL W.;JAYARAMAN, SHYAMALA C.;REEL/FRAME:019087/0573 Effective date: 20070329 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |